China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II clinical study for its pipeline candidate drug AR882, co-developed with Arthrosi Therapeutics Inc., for the treatment of gout. The randomized, placebo-controlled global study involved 42 patients, and after 6 weeks of treatment, results indicated that AR882 significantly reduced serum uric acid (sUA) levels in gout sufferers, alleviated disease symptoms, and dissolved the volume of urate crystals. The drug demonstrated better efficacy and higher safety compared to existing therapies for treating gout patients.
AR882’s Efficacy and Safety Profile in Gout Management
AR882 is a highly effective and selective uric acid transporter (URAT1) inhibitor that promotes the normalization of urine urate excretion and reduces sUA levels. Unlike other anti-gout drugs such as benzbromarone, AR882 can bind to the uric acid transporter for an extended period, prolonging inhibition. Clinical results showed that its efficacy lasted up to 24 hours. Moreover, its ability to block the reabsorption of uric acid around the clock does not increase kidney load, indicating no nephrotoxicity.- Flcube.com
